Supporting Patients with Compromised Absorption

Survimed® OPD is an oligo-peptide-based nutrition range developed for patients with malabsorption, available as both tube feeds and oral nutritional supplements.

An older couple sit together at home alongside the Survimed OPD range of tube feeds and oral nutritional supplements, developed for patients with malabsorption.

Supporting Patients with Compromised Absorption

Formulated Around the Principles of Semi-Elemental Nutrition

When gastrointestinal function is compromised, intact proteins and long-chain fats can be poorly digested and absorbed. Survimed OPD* addresses this by applying semi-elemental nutrition principles, using hydrolysed whey protein and an MCT-rich fat profile to support nutrient uptake where standard formulas may not be tolerated.^1,2

Peptide-Based Protein for Improved Digestibility

By delivering protein predominantly in peptide form, Survimed OPD reduces the enzymatic burden of digestion, supporting protein absorption in patients with impaired digestive capacity.^1,3

Adapted Fat Profile with a High Proportion of MCT

Medium-chain triglycerides (MCT) require less enzymatic processing than long-chain fats, making them a well-suited energy source for patients where fat malabsorption is a clinical concern.²

Fibre-Free Formulations to Support Tolerance

Fibre is omitted across the Survimed OPD range, making it appropriate for patients where fibre may exacerbate gastrointestinal symptoms or further compromise tolerance.

A Flexible Range That Covers Tube and Oral Feeding

Survimed OPD is available in two tube feed variants and two oral nutritional supplements; the range applies consistent semi-elemental nutritional principles across both tube and oral feeding routes. High-protein and high-energy options are also available.

All products are clinically free from lactose and gluten and can be used as a sole source of nutrition, depending on the format and dosage, under medical supervision.

A young boy and an older man spend time together at the beach, supporting Survimed OPD's flexible range of tube feeds and oral nutritional supplements for patients with malabsorption.

Tube Feeds and Sip Feeds to Match Clinical Requirements

Survimed OPD is available in EasyBottle and EasyBag formats, including:

Survimed OPD: 1.0 kcal/ml;18 energy% hydrolysed whey protein; 52 % of fat as MCT; Fibre free; 500 ml and 1000 ml EasyBag

Survimed OPD HN: 1.33 kcal/ml; 20 energy% hydrolysed whey protein; 52% of fat as MCT; Fibre free; 500 ml EasyBag;

Survimed OPD Drink: 1.0 kcal/ml 18 energy% hydrolysed whey protein; 48 % of fat as MCT; Fibre free; 200 ml EasyBottle; Vanilla

Survimed OPD 1.5 KCAL Drink: 1.5 kcal/ml ; 20 energy% hydrolysed whey protein; 50 % of fat as MCT; Fibre free; 200 ml EasyBottle; ; Vanilla and Cappuccino

The Survimed OPD range includes Survimed OPD and OPD HN tube feeds alongside OPD Drink and OPD 1.5 KCAL Drink oral nutritional supplements.

Fresubin® ONS

Discover our wide range of Oral Nutritional Supplements.

Fresubin® Tube Feeds

Explore Fresubin®'s Tube Feed Ranges.

Survimed factsheets can be downloaded here:

Survimed OPD 1.5 KCAL Drink Factsheet

Filename: Survimed_OPD1.5kcalDrink_FS_HCP_Nov2022.pdf
Size: 287 KB
Format: pdf

Sruvimed OPD Drink Factsheet

Filename: Survimed_OPDDrink_FS_HCP_Jun2022.pdf
Size: 308 KB
Format: pdf

Survimed OPD HN Factsheet

Filename: SurvimedOPDHN_FS_HCP_Nov22.pdf
Size: 1 MB
Format: pdf

Survimed OPD Factsheet

Filename: Survimed_OPD_Factsheet_viewPDF_Dec2024.pdf
Size: 1 MB
Format: pdf

*Survimed products are food for special medical purposes, to be used under medical supervision. For the dietary management of patients with or at risk of disease related malnutrition in particular with malabsorption. Suitable as sole source of nutrition depending on format and dosage. Not suitable for children under 3 years or patients with galactosaemia. Use with caution in children under 6 years. Not for parenteral (I.V.) use. For Healthcare Professionals only.

References:

¹ Alexander DD et al. World J Gastrointest Pharmacol Ther. 2016;7(2):306-19.
² Babayan VK. Lipids. 1987;22(6):417-20.
³ Hegazi RA et al. Crit Care. 2011;15(6):234.